Global Immuno-oncology Drugs Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
Table of Contents1 Report Overview
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Immuno-oncology Drugs Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Immune System Modulators
1.2.4 Cancer Vaccines
1.2.5 Oncolytic Virus
1.2.6 Others
1.3 Market Segment by Application
1.3.1 Global Immuno-oncology Drugs Market Share by Application (2017 VS 2021 VS 2028)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Immuno-oncology Drugs Market Size (2017-2028)
2.1.1 Global Immuno-oncology Drugs Revenue (2017-2028)
2.1.2 Global Immuno-oncology Drugs Sales (2017-2028)
2.2 Global Immuno-oncology Drugs Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.2.1 Global Immuno-oncology Drugs Sales by Regions (2017-2022)
2.2.2 Global Immuno-oncology Drugs Revenue by Regions (2017-2022)
2.3 Global Immuno-oncology Drugs Market Size Forecast by Region
2.3.1 Global Immuno-oncology Drugs Sales Forecast by Region (2023-2028)
2.3.2 Global Immuno-oncology Drugs Revenue Forecast by Region (2023-2028)
2.4 Global Top Immuno-oncology Drugs Regions (Countries) Ranking by Market Size
2.5 Immuno-oncology Drugs Market Dynamics
2.5.1 Immuno-oncology Drugs Market Trends
2.5.2 Immuno-oncology Drugs Market Drivers
2.5.3 Immuno-oncology Drugs Market Challenges
2.5.4 Immuno-oncology Drugs Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Immuno-oncology Drugs Manufacturers by Sales (2017-2022)
3.1.1 Global Immuno-oncology Drugs Sales by Manufacturers (2017-2022)
3.1.2 Global Immuno-oncology Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global 5 and 10 Largest Manufacturers by Immuno-oncology Drugs Sales in 2021
3.2 Global Top Manufacturers Immuno-oncology Drugs by Revenue
3.2.1 Global Immuno-oncology Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Top Immuno-oncology Drugs Manufacturers Covered: Ranking by Revenue
3.2.3 Global Immuno-oncology Drugs Revenue Share by Manufacturers (2017-2022)
3.2.4 Global Immuno-oncology Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Immuno-oncology Drugs as of 2021)
3.4 Global Immuno-oncology Drugs Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Immuno-oncology Drugs Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Immuno-oncology Drugs Market
3.7 Key Manufacturers Immuno-oncology Drugs Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Immuno-oncology Drugs Market Size by Type
4.1 Global Immuno-oncology Drugs Historic Market Review by Type (2017-2022)
4.1.1 Global Immuno-oncology Drugs Sales Market Share by Type (2017-2022)
4.1.2 Global Immuno-oncology Drugs Revenue Market Share by Type (2017-2022)
4.1.3 Immuno-oncology Drugs Price by Type (2017-2022)
4.2 Global Immuno-oncology Drugs Market Estimates and Forecasts by Type (2023-2028)
4.2.1 Global Immuno-oncology Drugs Sales Forecast by Type (2023-2028)
4.2.2 Global Immuno-oncology Drugs Revenue Forecast by Type (2023-2028)
4.2.3 Immuno-oncology Drugs Price Forecast by Type (2023-2028)
5 Global Immuno-oncology Drugs Market Size by Application
5.1 Global Immuno-oncology Drugs Historic Market Review by Application (2017-2022)
5.1.1 Global Immuno-oncology Drugs Sales Market Share by Application (2017-2022)
5.1.2 Global Immuno-oncology Drugs Revenue Market Share by Application (2017-2022)
5.1.3 Immuno-oncology Drugs Price by Application (2017-2022)
5.2 Global Immuno-oncology Drugs Market Estimates and Forecasts by Application (2023-2028)
5.2.1 Global Immuno-oncology Drugs Sales Forecast by Application (2023-2028)
5.2.2 Global Immuno-oncology Drugs Revenue Forecast by Application (2023-2028)
5.2.3 Immuno-oncology Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Immuno-oncology Drugs Sales Breakdown by Company
6.1.1 North America Immuno-oncology Drugs Sales by Company (2017-2022)
6.1.2 North America Immuno-oncology Drugs Revenue by Company (2017-2022)
6.2 North America Immuno-oncology Drugs Market Size by Type
6.2.1 North America Immuno-oncology Drugs Sales by Type (2017-2028)
6.2.2 North America Immuno-oncology Drugs Revenue by Type (2017-2028)
6.3 North America Immuno-oncology Drugs Market Size by Application
6.3.1 North America Immuno-oncology Drugs Sales by Application (2017-2028)
6.3.2 North America Immuno-oncology Drugs Revenue by Application (2017-2028)
6.4 North America Immuno-oncology Drugs Market Size by Country
6.4.1 North America Immuno-oncology Drugs Sales by Country (2017-2028)
6.4.2 North America Immuno-oncology Drugs Revenue by Country (2017-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Immuno-oncology Drugs Sales Breakdown by Company
7.1.1 Europe Immuno-oncology Drugs Sales by Company (2017-2022)
7.1.2 Europe Immuno-oncology Drugs Revenue by Company (2017-2022)
7.2 Europe Immuno-oncology Drugs Market Size by Type
7.2.1 Europe Immuno-oncology Drugs Sales by Type (2017-2028)
7.2.2 Europe Immuno-oncology Drugs Revenue by Type (2017-2028)
7.3 Europe Immuno-oncology Drugs Market Size by Application
7.3.1 Europe Immuno-oncology Drugs Sales by Application (2017-2028)
7.3.2 Europe Immuno-oncology Drugs Revenue by Application (2017-2028)
7.4 Europe Immuno-oncology Drugs Market Size by Country
7.4.1 Europe Immuno-oncology Drugs Sales by Country (2017-2028)
7.4.2 Europe Immuno-oncology Drugs Revenue by Country (2017-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Immuno-oncology Drugs Sales Breakdown by Company
8.1.1 Asia Pacific Immuno-oncology Drugs Sales by Company (2017-2022)
8.1.2 Asia Pacific Immuno-oncology Drugs Revenue by Company (2017-2022)
8.2 Asia Pacific Immuno-oncology Drugs Market Size by Type
8.2.1 Asia Pacific Immuno-oncology Drugs Sales by Type (2017-2028)
8.2.2 Asia Pacific Immuno-oncology Drugs Revenue by Type (2017-2028)
8.3 Asia Pacific Immuno-oncology Drugs Market Size by Application
8.3.1 Asia Pacific Immuno-oncology Drugs Sales by Application (2017-2028)
8.3.2 Asia Pacific Immuno-oncology Drugs Revenue by Application (2017-2028)
8.4 Asia Pacific Immuno-oncology Drugs Market Size by Region
8.4.1 Asia Pacific Immuno-oncology Drugs Sales by Region
8.4.2 Asia Pacific Immuno-oncology Drugs Revenue by Region
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Immuno-oncology Drugs Sales Breakdown by Company
9.1.1 Latin America Immuno-oncology Drugs Sales by Company (2017-2022)
9.1.2 Latin America Immuno-oncology Drugs Revenue by Company (2017-2022)
9.2 Latin America Immuno-oncology Drugs Market Size by Type
9.2.1 Latin America Immuno-oncology Drugs Sales by Type (2017-2028)
9.2.2 Latin America Immuno-oncology Drugs Revenue by Type (2017-2028)
9.3 Latin America Immuno-oncology Drugs Market Size by Application
9.3.1 Latin America Immuno-oncology Drugs Sales by Application (2017-2028)
9.3.2 Latin America Immuno-oncology Drugs Revenue by Application (2017-2028)
9.4 Latin America Immuno-oncology Drugs Market Size by Country
9.4.1 Latin America Immuno-oncology Drugs Sales by Country (2017-2028)
9.4.2 Latin America Immuno-oncology Drugs Revenue by Country (2017-2028)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Immuno-oncology Drugs Sales Breakdown by Company
10.1.1 Middle East and Africa Immuno-oncology Drugs Sales by Company (2017-2022)
10.1.2 Middle East and Africa Immuno-oncology Drugs Revenue by Company (2017-2022)
10.2 Middle East and Africa Immuno-oncology Drugs Market Size by Type
10.2.1 Middle East and Africa Immuno-oncology Drugs Sales by Type (2017-2028)
10.2.2 Middle East and Africa Immuno-oncology Drugs Revenue by Type (2017-2028)
10.3 Middle East and Africa Immuno-oncology Drugs Market Size by Application
10.3.1 Middle East and Africa Immuno-oncology Drugs Sales by Application (2017-2028)
10.3.2 Middle East and Africa Immuno-oncology Drugs Revenue by Application (2017-2028)
10.4 Middle East and Africa Immuno-oncology Drugs Market Size by Country
10.4.1 Middle East and Africa Immuno-oncology Drugs Sales by Country (2017-2028)
10.4.2 Middle East and Africa Immuno-oncology Drugs Revenue by Country (2017-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 U.A.E
11 Company Profiles
11.1 Amgen, Inc
11.1.1 Amgen, Inc Corporation Information
11.1.2 Amgen, Inc Overview
11.1.3 Amgen, Inc Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.1.4 Amgen, Inc Immuno-oncology Drugs Products and Services
11.1.5 Amgen, Inc Immuno-oncology Drugs SWOT Analysis
11.1.6 Amgen, Inc Recent Developments
11.2 AstraZeneca, Plc
11.2.1 AstraZeneca, Plc Corporation Information
11.2.2 AstraZeneca, Plc Overview
11.2.3 AstraZeneca, Plc Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.2.4 AstraZeneca, Plc Immuno-oncology Drugs Products and Services
11.2.5 AstraZeneca, Plc Immuno-oncology Drugs SWOT Analysis
11.2.6 AstraZeneca, Plc Recent Developments
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Corporation Information
11.3.2 Bristol-Myers Squibb Overview
11.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.3.4 Bristol-Myers Squibb Immuno-oncology Drugs Products and Services
11.3.5 Bristol-Myers Squibb Immuno-oncology Drugs SWOT Analysis
11.3.6 Bristol-Myers Squibb Recent Developments
11.4 Celgene Corporation
11.4.1 Celgene Corporation Corporation Information
11.4.2 Celgene Corporation Overview
11.4.3 Celgene Corporation Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.4.4 Celgene Corporation Immuno-oncology Drugs Products and Services
11.4.5 Celgene Corporation Immuno-oncology Drugs SWOT Analysis
11.4.6 Celgene Corporation Recent Developments
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Corporation Information
11.5.2 Eli Lilly and Company Overview
11.5.3 Eli Lilly and Company Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.5.4 Eli Lilly and Company Immuno-oncology Drugs Products and Services
11.5.5 Eli Lilly and Company Immuno-oncology Drugs SWOT Analysis
11.5.6 Eli Lilly and Company Recent Developments
11.6 Merck & Co.
11.6.1 Merck & Co. Corporation Information
11.6.2 Merck & Co. Overview
11.6.3 Merck & Co. Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.6.4 Merck & Co. Immuno-oncology Drugs Products and Services
11.6.5 Merck & Co. Immuno-oncology Drugs SWOT Analysis
11.6.6 Merck & Co. Recent Developments
11.7 Hoffmann-La Roche AG
11.7.1 Hoffmann-La Roche AG Corporation Information
11.7.2 Hoffmann-La Roche AG Overview
11.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.7.4 Hoffmann-La Roche AG Immuno-oncology Drugs Products and Services
11.7.5 Hoffmann-La Roche AG Immuno-oncology Drugs SWOT Analysis
11.7.6 Hoffmann-La Roche AG Recent Developments
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Corporation Information
11.8.2 Johnson & Johnson Overview
11.8.3 Johnson & Johnson Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.8.4 Johnson & Johnson Immuno-oncology Drugs Products and Services
11.8.5 Johnson & Johnson Immuno-oncology Drugs SWOT Analysis
11.8.6 Johnson & Johnson Recent Developments
11.9 Novartis International AG
11.9.1 Novartis International AG Corporation Information
11.9.2 Novartis International AG Overview
11.9.3 Novartis International AG Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.9.4 Novartis International AG Immuno-oncology Drugs Products and Services
11.9.5 Novartis International AG Immuno-oncology Drugs SWOT Analysis
11.9.6 Novartis International AG Recent Developments
11.10 AbbVie, Inc.
11.10.1 AbbVie, Inc. Corporation Information
11.10.2 AbbVie, Inc. Overview
11.10.3 AbbVie, Inc. Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.10.4 AbbVie, Inc. Immuno-oncology Drugs Products and Services
11.10.5 AbbVie, Inc. Immuno-oncology Drugs SWOT Analysis
11.10.6 AbbVie, Inc. Recent Developments
11.11 Pfizer Inc.
11.11.1 Pfizer Inc. Corporation Information
11.11.2 Pfizer Inc. Overview
11.11.3 Pfizer Inc. Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.11.4 Pfizer Inc. Immuno-oncology Drugs Products and Services
11.11.5 Pfizer Inc. Recent Developments
11.12 Sanofi S.A.
11.12.1 Sanofi S.A. Corporation Information
11.12.2 Sanofi S.A. Overview
11.12.3 Sanofi S.A. Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.12.4 Sanofi S.A. Immuno-oncology Drugs Products and Services
11.12.5 Sanofi S.A. Recent Developments
11.13 EMD Serono, Inc.
11.13.1 EMD Serono, Inc. Corporation Information
11.13.2 EMD Serono, Inc. Overview
11.13.3 EMD Serono, Inc. Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.13.4 EMD Serono, Inc. Immuno-oncology Drugs Products and Services
11.13.5 EMD Serono, Inc. Recent Developments
11.14 Gilead Sciences Inc.
11.14.1 Gilead Sciences Inc. Corporation Information
11.14.2 Gilead Sciences Inc. Overview
11.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.14.4 Gilead Sciences Inc. Immuno-oncology Drugs Products and Services
11.14.5 Gilead Sciences Inc. Recent Developments
11.15 Prometheus Therapeutics & Diagnostics
11.15.1 Prometheus Therapeutics & Diagnostics Corporation Information
11.15.2 Prometheus Therapeutics & Diagnostics Overview
11.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.15.4 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Products and Services
11.15.5 Prometheus Therapeutics & Diagnostics Recent Developments
11.16 Aduro BioTech
11.16.1 Aduro BioTech Corporation Information
11.16.2 Aduro BioTech Overview
11.16.3 Aduro BioTech Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.16.4 Aduro BioTech Immuno-oncology Drugs Products and Services
11.16.5 Aduro BioTech Recent Developments
11.17 Galena Biopharma
11.17.1 Galena Biopharma Corporation Information
11.17.2 Galena Biopharma Overview
11.17.3 Galena Biopharma Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.17.4 Galena Biopharma Immuno-oncology Drugs Products and Services
11.17.5 Galena Biopharma Recent Developments
11.18 Bavarian Nordic
11.18.1 Bavarian Nordic Corporation Information
11.18.2 Bavarian Nordic Overview
11.18.3 Bavarian Nordic Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.18.4 Bavarian Nordic Immuno-oncology Drugs Products and Services
11.18.5 Bavarian Nordic Recent Developments
11.19 Celldex Therapeutics
11.19.1 Celldex Therapeutics Corporation Information
11.19.2 Celldex Therapeutics Overview
11.19.3 Celldex Therapeutics Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.19.4 Celldex Therapeutics Immuno-oncology Drugs Products and Services
11.19.5 Celldex Therapeutics Recent Developments
11.20 ImmunoCellular Therapeutics
11.20.1 ImmunoCellular Therapeutics Corporation Information
11.20.2 ImmunoCellular Therapeutics Overview
11.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.20.4 ImmunoCellular Therapeutics Immuno-oncology Drugs Products and Services
11.20.5 ImmunoCellular Therapeutics Recent Developments
11.21 Incyte
11.21.1 Incyte Corporation Information
11.21.2 Incyte Overview
11.21.3 Incyte Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.21.4 Incyte Immuno-oncology Drugs Products and Services
11.21.5 Incyte Recent Developments
11.22 Dendreon Corporation
11.22.1 Dendreon Corporation Corporation Information
11.22.2 Dendreon Corporation Overview
11.22.3 Dendreon Corporation Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.22.4 Dendreon Corporation Immuno-oncology Drugs Products and Services
11.22.5 Dendreon Corporation Recent Developments
11.23 Agilent Technologies Inc.
11.23.1 Agilent Technologies Inc. Corporation Information
11.23.2 Agilent Technologies Inc. Overview
11.23.3 Agilent Technologies Inc. Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.23.4 Agilent Technologies Inc. Immuno-oncology Drugs Products and Services
11.23.5 Agilent Technologies Inc. Recent Developments
11.24 Agenus Inc.
11.24.1 Agenus Inc. Corporation Information
11.24.2 Agenus Inc. Overview
11.24.3 Agenus Inc. Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.24.4 Agenus Inc. Immuno-oncology Drugs Products and Services
11.24.5 Agenus Inc. Recent Developments
11.25 Enzo Biochem, Inc.
11.25.1 Enzo Biochem, Inc. Corporation Information
11.25.2 Enzo Biochem, Inc. Overview
11.25.3 Enzo Biochem, Inc. Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.25.4 Enzo Biochem, Inc. Immuno-oncology Drugs Products and Services
11.25.5 Enzo Biochem, Inc. Recent Developments
11.26 Lonza Group
11.26.1 Lonza Group Corporation Information
11.26.2 Lonza Group Overview
11.26.3 Lonza Group Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.26.4 Lonza Group Immuno-oncology Drugs Products and Services
11.26.5 Lonza Group Recent Developments
11.27 Bio-Rad Laboratories, Inc.
11.27.1 Bio-Rad Laboratories, Inc. Corporation Information
11.27.2 Bio-Rad Laboratories, Inc. Overview
11.27.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.27.4 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Products and Services
11.27.5 Bio-Rad Laboratories, Inc. Recent Developments
11.28 Avantor, Inc.
11.28.1 Avantor, Inc. Corporation Information
11.28.2 Avantor, Inc. Overview
11.28.3 Avantor, Inc. Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.28.4 Avantor, Inc. Immuno-oncology Drugs Products and Services
11.28.5 Avantor, Inc. Recent Developments
11.29 Spring Bank Pharmaceuticals, Inc.
11.29.1 Spring Bank Pharmaceuticals, Inc. Corporation Information
11.29.2 Spring Bank Pharmaceuticals, Inc. Overview
11.29.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.29.4 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Products and Services
11.29.5 Spring Bank Pharmaceuticals, Inc. Recent Developments
11.30 Ferring Pharmaceuticals
11.30.1 Ferring Pharmaceuticals Corporation Information
11.30.2 Ferring Pharmaceuticals Overview
11.30.3 Ferring Pharmaceuticals Immuno-oncology Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.30.4 Ferring Pharmaceuticals Immuno-oncology Drugs Products and Services
11.30.5 Ferring Pharmaceuticals Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Immuno-oncology Drugs Value Chain Analysis
12.2 Immuno-oncology Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Immuno-oncology Drugs Production Mode & Process
12.4 Immuno-oncology Drugs Sales and Marketing
12.4.1 Immuno-oncology Drugs Sales Channels
12.4.2 Immuno-oncology Drugs Distributors
12.5 Immuno-oncology Drugs Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
List of TablesTable 1. Global Immuno-oncology Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Immune Checkpoint Inhibitors
Table 3. Major Manufacturers of Immune System Modulators
Table 4. Major Manufacturers of Cancer Vaccines
Table 5. Major Manufacturers of Oncolytic Virus
Table 6. Major Manufacturers of Others
Table 7. Global Immuno-oncology Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Immuno-oncology Drugs Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 9. Global Immuno-oncology Drugs Sales by Region (2017-2022) & (K Units)
Table 10. Global Immuno-oncology Drugs Sales Market Share by Region (2017-2022)
Table 11. Global Immuno-oncology Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Immuno-oncology Drugs Revenue Market Share by Region (2017-2022)
Table 13. Global Immuno-oncology Drugs Sales Forecast by Region (2023-2028) & (K Units)
Table 14. Global Immuno-oncology Drugs Sales Market Share Forecast by Region (2023-2028)
Table 15. Global Immuno-oncology Drugs Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 16. Global Immuno-oncology Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 17. Top Immuno-oncology Drugs Regions (Countries) Ranking by Market Size (US$ Million) in 2021
Table 18. Immuno-oncology Drugs Market Trends
Table 19. Immuno-oncology Drugs Market Drivers
Table 20. Immuno-oncology Drugs Market Challenges
Table 21. Immuno-oncology Drugs Market Restraints
Table 22. Global Immuno-oncology Drugs Sales by Manufacturers (2017-2022) & (K Units)
Table 23. Global Immuno-oncology Drugs Sales Share by Manufacturers (2017-2022)
Table 24. Global Immuno-oncology Drugs Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 25. Ranking of Global Top Immuno-oncology Drugs Manufacturers by Revenue (US$ Million) in 2021
Table 26. Immuno-oncology Drugs Revenue Share by Manufacturers (2017-2022)
Table 27. Global Immuno-oncology Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Immuno-oncology Drugs as of 2021)
Table 29. Key Manufacturers Immuno-oncology Drugs Average Selling Price (ASP) & (2017-2022) & (USD/Unit)
Table 30. Key Manufacturers Immuno-oncology Drugs Plants/Factories Distribution
Table 31. Key Manufacturers Immuno-oncology Drugs Area Served
Table 32. Date of Key Manufacturers Enter into Immuno-oncology Drugs Market
Table 33. Key Manufacturers Immuno-oncology Drugs Product Type
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global Immuno-oncology Drugs Sales (K Units) by Type (2017-2022)
Table 36. Global Immuno-oncology Drugs Sales Share by Type (2017-2022)
Table 37. Global Immuno-oncology Drugs Revenue (US$ Million) Market Share by Type (2017-2022)
Table 38. Global Immuno-oncology Drugs Price (K Units) by Type (2017-2022)
Table 39. Global Immuno-oncology Drugs Sales (K Units) by Type (2023-2028)
Table 40. Global Immuno-oncology Drugs Sales Share by Type (2023-2028)
Table 41. Global Immuno-oncology Drugs Revenue (US$ Million) Market Share by Type (2023-2028)
Table 42. Global Immuno-oncology Drugs Revenue Share by Type (2023-2028)
Table 43. Global Immuno-oncology Drugs Price (K Units) by Type (2023-2028)
Table 44. Global Immuno-oncology Drugs Sales (K Units) by Application (2017-2022)
Table 45. Global Immuno-oncology Drugs Sales Share by Application (2017-2022)
Table 46. Global Immuno-oncology Drugs Revenue (US$ Million) Market Share by Application (2017-2022)
Table 47. Global Immuno-oncology Drugs Price (K Units) by Application (2017-2022)
Table 48. Global Immuno-oncology Drugs Sales (K Units) by Application (2023-2028)
Table 49. Global Immuno-oncology Drugs Sales Share by Application (2023-2028)
Table 50. Global Immuno-oncology Drugs Revenue (US$ Million) Market Share by Application (2023-2028)
Table 51. Global Immuno-oncology Drugs Revenue Share by Application (2023-2028)
Table 52. Global Immuno-oncology Drugs Price (K Units) by Application (2023-2028)
Table 53. North America Immuno-oncology Drugs Sales by Company (2017-2022) & (K Units)
Table 54. North America Immuno-oncology Drugs Sales Market Share by Company (2017-2022)
Table 55. North America Immuno-oncology Drugs Revenue by Company (2017-2022) & (US$ Million)
Table 56. North America Immuno-oncology Drugs Revenue Market Share by Company (2017-2022)
Table 57. North America Immuno-oncology Drugs Sales by Type (2017-2022) & (K Units)
Table 58. North America Immuno-oncology Drugs Sales by Type (2023-2028) & (K Units)
Table 59. North America Immuno-oncology Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 60. North America Immuno-oncology Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 61. North America Immuno-oncology Drugs Sales by Application (2017-2022) & (K Units)
Table 62. North America Immuno-oncology Drugs Sales by Application (2023-2028) & (K Units)
Table 63. North America Immuno-oncology Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 64. North America Immuno-oncology Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 65. North America Immuno-oncology Drugs Sales by Country (2017-2022) & (K Units)
Table 66. North America Immuno-oncology Drugs Sales by Country (2023-2028) & (K Units)
Table 67. North America Immuno-oncology Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 68. North America Immuno-oncology Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 69. Europe Immuno-oncology Drugs Sales by Company (2017-2022) & (K Units)
Table 70. Europe Immuno-oncology Drugs Sales Market Share by Company (2017-2022)
Table 71. Europe Immuno-oncology Drugs Revenue by Company (2017-2022) & (US$ Million)
Table 72. Europe Immuno-oncology Drugs Revenue Market Share by Company (2017-2022)
Table 73. Europe Immuno-oncology Drugs Sales by Type (2017-2022) & (K Units)
Table 74. Europe Immuno-oncology Drugs Sales by Type (2023-2028) & (K Units)
Table 75. Europe Immuno-oncology Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 76. Europe Immuno-oncology Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 77. Europe Immuno-oncology Drugs Sales by Application (2017-2022) & (K Units)
Table 78. Europe Immuno-oncology Drugs Sales by Application (2023-2028) & (K Units)
Table 79. Europe Immuno-oncology Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 80. Europe Immuno-oncology Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 81. Europe Immuno-oncology Drugs Sales by Country (2017-2022) & (K Units)
Table 82. Europe Immuno-oncology Drugs Sales by Country (2023-2028) & (K Units)
Table 83. Europe Immuno-oncology Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 84. Europe Immuno-oncology Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 85. Asia Pacific Immuno-oncology Drugs Sales by Company (2017-2022) & (K Units)
Table 86. Asia Pacific Immuno-oncology Drugs Sales Market Share by Company (2017-2022)
Table 87. Asia Pacific Immuno-oncology Drugs Revenue by Company (2017-2022) & (US$ Million)
Table 88. Asia Pacific Immuno-oncology Drugs Revenue Market Share by Company (2017-2022)
Table 89. Asia Pacific Immuno-oncology Drugs Sales by Type (2017-2022) & (K Units)
Table 90. Asia Pacific Immuno-oncology Drugs Sales by Type (2023-2028) & (K Units)
Table 91. Asia Pacific Immuno-oncology Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 92. Asia Pacific Immuno-oncology Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 93. Asia Pacific Immuno-oncology Drugs Sales by Application (2017-2022) & (K Units)
Table 94. Asia Pacific Immuno-oncology Drugs Sales by Application (2023-2028) & (K Units)
Table 95. Asia Pacific Immuno-oncology Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 96. Asia Pacific Immuno-oncology Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 97. Asia Pacific Immuno-oncology Drugs Sales by Region (2017-2022) & (K Units)
Table 98. Asia Pacific Immuno-oncology Drugs Sales by Region (2023-2028) & (K Units)
Table 99. Asia Pacific Immuno-oncology Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 100. Asia Pacific Immuno-oncology Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 101. Latin America Immuno-oncology Drugs Sales by Company (2017-2022) & (K Units)
Table 102. Latin America Immuno-oncology Drugs Sales Market Share by Company (2017-2022)
Table 103. Latin America Immuno-oncology Drugs Revenue by Company (2017-2022) & (US$ Million)
Table 104. Latin America Immuno-oncology Drugs Revenue Market Share by Company (2017-2022)
Table 105. Latin America Immuno-oncology Drugs Sales by Type (2017-2022) & (K Units)
Table 106. Latin America Immuno-oncology Drugs Sales by Type (2023-2028) & (K Units)
Table 107. Latin America Immuno-oncology Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 108. Latin America Immuno-oncology Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 109. Latin America Immuno-oncology Drugs Sales